Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Hereditary Cancer in Clinical Practice - United Kingdom
doi 10.1186/1897-4287-9-s2-a4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Response to Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

Cisplatin in Breast Cancer Treatment in BRCA1 Carriers

Hereditary Cancer in Clinical Practice
OncologyGenetics
2012English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

Neoadjuvant Systemic Therapy in Breast Cancer

2012English

Impact of Clinicopathological Characteristics on the Efficacy of Neoadjuvant Therapy in Patients With Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Efficacy of Neoadjuvant Therapy With Trastuzumab Concurrent With Anthracycline- And Nonanthracycline-Based Regimens for HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2011English

Lurbinectedin Is Active in Patients With BRCA1/2 Mutant Breast Cancer

Cancer Discovery
Oncology
2018English

Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Complete Pathological Response in Patients With Locally Advanced Cancer of Breast and Positive Her2/Neu With Neoadjuvant Chemotherapy

BMC Cancer
Cancer ResearchOncologyGenetics
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy